Shipments of AI Servers Will Climb at CAGR of 10.8% from 2022 to 2026, Says TrendForce
TAIPEI, Taiwan--(BUSINESS WIRE)--#AI--According to TrendForce’s latest survey of the server market, many cloud service providers…
4 years ago
Asia Pacific Spintronics Market Report to 2031: Players Include Avalanche Technology, Crocus Technology, Everspin Technologies, IBM and Intel – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Spintronics Market 2021-2031 by Device Type, Application, Industry Vertical, and Country:…
4 years ago
Asia Pacific Spintronics Market Report to 2031: Players Include Avalanche Technology, Crocus Technology, Everspin Technologies, IBM and Intel – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Spintronics Market 2021-2031 by Device Type, Application, Industry Vertical, and Country:…
4 years ago
Asia Pacific Spintronics Market Report to 2031: Players Include Avalanche Technology, Crocus Technology, Everspin Technologies, IBM and Intel – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Spintronics Market 2021-2031 by Device Type, Application, Industry Vertical, and Country:…
4 years ago
Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy
TOKYO--(BUSINESS WIRE)--Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji…
4 years ago
Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy
TOKYO--(BUSINESS WIRE)--Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji…
4 years ago
Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy
TOKYO--(BUSINESS WIRE)--Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji…
4 years ago
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors
GUANGZHOU, China--(BUSINESS WIRE)--#ADC--Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing…
4 years ago
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors
GUANGZHOU, China--(BUSINESS WIRE)--#ADC--Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing…
4 years ago
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors
GUANGZHOU, China--(BUSINESS WIRE)--#ADC--Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing…
4 years ago